Immune Microenvironment Change and Involvement of Circular RNAs in TIL Cells of Recurrent Nasopharyngeal Carcinoma

Wang, Yumin; Peng, Zhouying; Wang, Yaxuan; Yang, Yi; Fan, Ruohao; Gao, Kelei; Zhang, Hua; Xie, Zhihai; Jiang, Weihong

doi:10.3389/fcell.2021.722224

Cited by 8 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Predina et al [33] demonstrated that recurrent tumours and draining lymph nodes are infiltrated with M2 macrophages and CD4 + Foxp3 + regulatory T cells. Furthermore, the composition of tumour-infiltrating T cells significantly changes during the recurrence of cancer, especially the increase of Treg and the CD4 + /CD8 + ratio [34]. In the CD4 + T cells fractions, T helper 1/T helper 2 (Th1/Th2) cells are considered to differentially up-regulate PD-L1 and PD-L2 expression on inflammatory macrophages [35].…”

Section: Discussionmentioning

confidence: 99%

PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

Wada,

Kamijo,

Shimomura

et al. 2023

Immunology

View full text Add to dashboard Cite

BackgroundThe tumour microenvironment (TME), which is modulated after immune‐chemotherapy, is involved in tumour growth and metastasis. Programmed cell death 1 (PD‐1) expressed on tumour‐infiltrating non‐malignant cells plays an important role in the TME through the PD‐1/programmed cell death ligand 1 (PD‐L1) signalling pathway. However, its impact in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) remains unclear.MethodsWe conducted a retrospective study using tissue samples at relapse for patients with R/R DLBCL (n = 45) and evaluated the clinical impact of PD‐1 expression on tumour‐infiltrating non‐malignant cells (microenvironmental PD‐1, mPD‐1). In addition, corresponding 27 samples at diagnosis were analysed to evaluate the changes in PD‐1/PD‐L1 expression in the TME after chemotherapy.ResultsPatients with mPD‐1+ DLBCL showed significantly better overall survival compared with patients with mPD‐1− DLBCL (hazard ratio, 0.30, p = 0.03). Among patients with mPD‐1− DLBCL, those positive for neoplastic or microenvironmental PD‐L1 (nPD‐L1+ or mPD‐L1+) showed significantly worse outcomes. Microenvironmental PD‐1 and PD‐L1 expression has high correlation at relapse, although none was found at diagnosis.ConclusionWe determined the clinical impact of microenvironmental PD‐1 expression and its relationship with neoplastic or microenvironmental expression of PD‐L1 in patients with R/R DLBCL. The expression of PD‐1 and PD‐L1 in the TME dramatically changes during the chemotherapy. Therefore, evaluating TME at relapse, not at diagnosis is useful to predict the outcomes of R/R DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

Wada,

Kamijo,

Shimomura

et al. 2023

Immunology

View full text Add to dashboard Cite

show abstract

“…CircRNAs (circ0000831, circ005019, circ0031584 circ0006935 and circ0001730) have been revealed to induce changes in the TME of recurrent nasopharyngeal carcinoma. Altered distribution of immune cells and a decline in the ratio of CD4 + /CD8 + T cells were observed in the presence of these circRNAs (225). Targeting T cell activation by inhibiting the checkpoints such as the PD-1/PD-L1 pathway is termed checkpoint immunotherapy (226).…”

Section: Role Of Circrnas In Immunotherapy and Tumor Immunologymentioning

confidence: 99%

Recent progress of circular RNAs in different types of human cancer: Technological landscape, clinical opportunities and challenges (Review)

et al. 2022

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are a novel class of endogenous non-coding RNAs that have been recently regarded as functionally active. CircRNAs are remarkably stable and known to possess several biological functions such as microRNA sponging, regulating transcription and splicing and occasionally acting as polypeptide-producing templates. CircRNAs show tissue-specific expression and have been reported to be associated with the progression of several types of malignancies. Given the recent progress in genome sequencing and bioinformatics techniques, a rapid increment in the biological role of circRNAs has been observed. Concurrently, the patent search from different patent databases shows that the patent number of circRNA is increasing very quickly. These phenomena reveal a rapid development of the technological landscape. In the present review, the recent progress on circRNAs in various kinds of cancer has been investigated and their function as biomarkers or therapeutic targets and their technological landscape have been appreciated. A new insight into circRNAs structure and functional capabilities in cancer has been reviewed. Continually increasing knowledge on their critical role during cancer progression is projecting them as biomarkers or therapeutic targets for various kinds of cancer. Thus, recent updates on the functional role of circRNAs in terms of the technological landscape, clinical opportunities (biomarkers and therapeutic targets), and challenges in cancer have been illustrated.

show abstract

“…With the development of treatment techniques, the 5-year overall survival rate of NPC has reached 50-64%. However, 10-20% of patients with NPC still experience locoregional recurrence, metastasis, invasion, and radio resistance [4][5][6]. Therefore, determining biomarkers and potential mechanisms affecting carcinogenesis and recurrence is essential for developing a more personalized treatment for patients with NPC.…”

Section: Introductionmentioning

confidence: 99%

N6-Methyladenosine RNA Modification Landscape in the Occurrence and Recurrence of Nasopharyngeal Carcinoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Nasopharyngeal carcinoma (NPC) is a type of squamous head and neck cancer with variable geographic distributions, with the highest incidence in Southeast Asia. Its primary treatment is radiotherapy due to its high radio sensitivity. However, the N6methyladenosine (m6A) landscape in NPC, including recurrent NPC, has not been reported. Methods:In this study, m6A RNA immunoprecipitation (RIP) sequencing and microarray sequencing were performed on 12 tissue samples tissues of patients with primary and recurrent NPC. The expression profiles of m6A-related and non-coding RNAs were constructed and explored. Then, function experiments were performed to evaluate the effects of methyltransferase (METTL)3, METTL14 and WT1 associated protein (WTAP) on progressions of NPC. Finally, immunohistochemistry (IHC) and survival analysis were performed to confirm the correlation between METTL3, METTL14 and WTAP and NPC patients' clinical outcomes.Results: This study mapped m6A RNA modification and RNA expression profiles in normal nasopharynx, primary NPC, and recurrent NPC tissues. This study also explored the role of m6A modificators in NPC development and recurrence. METTL3, METTL14, and WTAP could promote invasion and metastasis of NPC, and that these three proteins could induce radiotherapy resistance in NPC cells through DNA repair. Moreover, we found that METTL3, METTL14, and WTAP promoted an increase in exosomes within NPC microenvironment.Conclusions: This study suggests that the alteration of m6A modification in primary and recurrent NPCs may play an important role in the development and progression of NPC.

show abstract

Immune Microenvironment Change and Involvement of Circular RNAs in TIL Cells of Recurrent Nasopharyngeal Carcinoma

Cited by 8 publications

References 32 publications

PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

Recent progress of circular RNAs in different types of human cancer: Technological landscape, clinical opportunities and challenges (Review)

N6-Methyladenosine RNA Modification Landscape in the Occurrence and Recurrence of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About